Great post Myles always appreciate your input - The potential is fantastic even at the very low end just a miserly 1 % would be $2 billion versus $400m !!!!!!!
Hi Wyn , I am humbled to be in the presence of a trader with 40 years experience absolutely "a legend in (one's) own mind" Wyn is indeed a living " contridiction in terms " or maybe just enjoys sealioning
Anyway far more importantly look forward to seeing AVCT incremental market cap value appreciate onwards & upwards please .
AVCT - Short term trades or long term investment or both your choice - Thank you Avacta for the long term investment opportunity,
Courtesy of twitter
"I believe this is what RAH is referring to.
isn't just a Covid OR Cancer play, it's even more than that. Unbeliveable share price given the mid to long term potential.
"As a matter of interest, who has/hasn't heard of Novartis," Novartis taking an interest in fibroblast activation FAP
"The Swiss pharma is licensing the rights to develop and commercialize treatments based on a library of radioligand compounds from iTheranostics, a subsidiary of Sofie Biosciences. Originally developed at the University of Heidelberg, these compounds target fibroblast activation protein, or FAP, a cell surface protein found in low levels in healthy tissue but found in high levels in common cancers.
Point Biopharma doing something similar with radiation therapy using their FAP technology https://www.pointbiopharma.com/science/canseek
Avacta have a license deal with PB/Tufts - AVA6000 currently testing in humans "pre|CISION™ technology Avacta’s proprietary pre|CISION ™ technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAP?) which is highly upregulated in the tumour microenvironment of most solid tumours compared with healthy tissues."
If as we hope AVA6000 works as envisaged then should open up all sorts of commercial possibilities for Avacta .
Yes CO agree think other sites extract copy/ data from the official clinical trial register and display summary detail .
Phase 1a ----- "• 15 to 20 patients" -- might be able to complete that part in 3 hospitals guess depends on patient availability and perhaps also easier to manage across fewer sites to begin with etc .
For Phase 1a
• Objective: Assess safety and tolerability of AVA6000; determine MTD and/or recommended dose for further development
• Approximately 4 Cohorts to achieve MTD
• 15 to 20 patients
• Patient Population: Locally advanced and/or metastatic pancreatic, colorectal, non-small cell lung, breast, head and neck (SCCHN), soft tissue sarcoma, ovarian and bladder cancer
MTD - Maximum Tolerated Dose"
Eliot Forster also -- Non Executive Chairman Member of Avacta board ( good to have deal makers AVCT board )
His F-star Therapeutics just inked a nice deal .
"F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics"
fyi : Oct 22, 2021, Recent research in USA & London the benefits of LFT
"Lateral Flow Tests Detect Most People At Risk Of Transmitting Covid-19"
Sorry -Documentation from Chinese site " It only recognizes the N protein and cannot detect the S protein " so current product paperwork on offer nothing to do with Avacta . However does not mean they may in the future offer via MEDUSA-19 - " AffiDX® SARS-CoV-2 Antigen Lateral Flow Test"
Anyway thought this article interesting
"Day 2 Antigen Test: Lateral Flow Test To Replace RT-PCR For Those Fully Vaccinated"
AS did say would update the market when advised on the LFT home use submission --- "• Excellent progress being made towards self-test regulatory approval with Medusa19 with the submission of the regulatory documentation to a notified body in Europe."
Avacta already have professional use :
• There will be an ongoing global need for sensitive and reliable COVID-19 testing for many years.
• AffiDX SARS-CoV-2 antigen flow test with market leading performance CE marked for professional use.
• UK manufacturing capacity 2-3 million per month scalable in UK and abroad
Commercial traction building through direct sales and distributors in UK, EU and overseas in key markets such as APAC region."
Hi @sarahstevens Thanks for that excellent post , very welcome views , fair & balanced summary . No disagreement from me .
Would like to add - Avacta board made some significant hires last 12 months , big hitters employed also replaced just about all the scientic advisors . Plus engaged excellent Principal Investigator cancer experts to run AVA6000 clinical trials .
Proves Avacta board /CEO will do what it takes to deliver with the help of JV partners increased sharehoder value .
Will take time perhaps years away however might also be some short term reward for those that like to trade the SP .
Atracting some new additional institutional major investors would also not go amiss .
Also would not be surpised to see Avacta promoting the company via capital markets events in USA next year ( not for placement funds as not required ) but to increase asset profile awareness to a bigger investor audience then perhaps move towards a NASDAQ listing late 2022/2023 .
Might be of interest https://issuu.com/globetech/docs/lmi-1021-72?fr=sYjI2ZDMyNTI4Mg
This article seems to back up the continued need for LFT antigen covid testing , ( bottom of page 1-& continued page 13 )
"Driven by Evolution of New SARS-CoV-2 Strains, Antigen Testing Seen to Show Rapid Growth
The global COVID-19 antigen test market is witnessing increasing demand due to the evolution of new strains of the SARSCoV-2 virus and increasing spikes in the instances of new COVID-19 infections.
These are the latest findings of Transparency Market Research (Albany, NY, USA;
www.transparencymarketresearch.com), a next-generation market intelligence provider.
Products in the global COVID19 antigen test market are expected to gain traction owing to Driven by Evolution of New SARS-CoV-2 Strains, Antigen Testing Seen to Show Rapid Growth
Products in the global COVID19 antigen test market are expected to gain traction owing to their benefits such as shorter test-to-result timeline, as well as their patient-friendly and easy-to-use nature. Furthermore, scalability and timeline challenges regarding PCR testing for the SARS-CoV-2 virus are among the major factors resulting in increased uptake of products in the global COVID-19 antigen test market.
Moreover, the emergence of several COVID-19 variants in countries such as Brazil, the UK, and South Africa has intensified the requirement for enhanced and rapid testing products, thus fueling the growth of the global COVID-19 antigen test market.
Increasing concerns over the frequency as well as spread of these variants are also anticipated to favor the expansion of the global COVID-19 antigen test market.
Furthermore, increased demand for low cost rapid test kits for conducting large scale testing in order to control the spike in COVID-19 cases in various underdeveloped economies is also expected to favor the expansion of the global COVID-19 antigen test market over the coming years.
Additionally, the rising number of product approvals as well as emergency use authorizations by regulatory bodies, coupled with various technological collaborations between several operating entities, is expected to intensify the competitive landscape of the global COVID-19 antigen test market, going forward. Geographically, Asia Pacific is anticipated to account for the largest share of the global COVID-19 antigen test market in terms of revenue, mainly du
e to the strong presence of various regional and local players who are actively innovating newer antigen tests, as well as the introduction of various new products by several up and coming start-ups in the region"
FYI WHITE, Andrew Mark Resigned on 28 July 2021
Medusa Lifesciences 23 July 2020
Check out Medusa delivery & product costs policy currently for Rapid Saliva Protein Test ( Not Avacta ) but gives an indication of their possible international selling reach .